279
Participants
Start Date
December 31, 2010
Primary Completion Date
July 31, 2012
Study Completion Date
February 28, 2013
ulodesine
Oral dose administered daily for 84 days.
Placebo
Oral dose administered daily for 84 days.
Birmingham
Mobile
Phoenix
Scottsdale
Tucson
Malvern
Anaheim
Burbank
Irvine
La Mesa
Los Angeles
Oceanside
Palm Springs
Paramount
Sacramento
San Jose
Walnut Creek
West Covina
DeLand
Edgewater
Gainesville
Miami
Oldsmar
Sanford
Atlanta
Honolulu
Meridian
Gurnee
Brownsburg
Newton
Lexington
Baltimore
Springfield
Lansing
Olive Branch
Omaha
Albuquerque
Charlotte
Greensboro
Raleigh
Salisbury
Winston-Salem
Cincinnati
Cleveland
Oklahoma City
Duncansville
Greer
Rapid City
Bristol
Dallas
San Antonio
Salt Lake City
Richmond
Tacoma
Lead Sponsor
BioCryst Pharmaceuticals
INDUSTRY